Company: SNSE
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046338
Chunk: 12

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 12
---
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors” section of this Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. 

In this section, we discuss our financial condition, changes in financial condition and results of our operations for the year ended December 31, 2024, compared to the year ended December 31, 2023. For a discussion and analysis comparing our results for the year ended December 31, 2023, to the year ended December 31, 2022, see our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on  February 29, 2024, under Part II, Item 7 "Management’s Discussion and Analysis of Financial Condition and Results of Operations."

Overview

We are a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through our TMAb™ (Tumor Microenvironment Activated Biologics) platform, we are developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Our strategy is to generate novel product candidates that incorporate next-generation technologies or approaches. We plan to efficiently develop these product candidates by incorporating state-of-the-art biomarker approaches and mechanistic understanding into clinical trial designs targeted to well-defined patient populations. 

We currently have one investigational product candidate, solnerstotug, in clinical development, and three preclinical product candidates.

•Solnerstotug (formerly referred to as SNS-101) is our conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation). 

oIn May 2023, we initiated a first-in-human Phase 1/2 open-label, multi-center, dose escalation and expansion trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of solnerstotug as monotherapy and/or in combination with cemiplimab in